BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 25, 2026
Home » Topics » Newco news

Newco news
Newco news RSS Feed RSS

Hand holding money plant

MBD and Azothbio partner for rare cancer drug using AI modeling technology

March 3, 2020
By Jihyun Kim
HONG KONG – MBD Co. Ltd. and Azothbio Inc., both based in South Korea, have entered an agreement for rare cancer drug development using an AI-powered drug discovery platform.
Read More
Newco news

Aivita Biomedical ahead of schedule on its phase II glioblastoma trial

Feb. 27, 2020
By Lee Landenberger
Aivita Biomedical Inc.’s CEO, Hans Keirstead, just finished up a $12.5 million fundraiser and he’s prepping for another $12.5 million in a second effort. In the two months since he started raising the money, he has hired four more people and plans to hire four more by year-end, bringing the company’s headcount to 36 employees.
Read More
Tuberculosis

Waveguide debuts portable NMR device

Feb. 26, 2020
By Meg Bryant
Waveguide Corp. has launched the first portable, battery-powered nuclear magnetic resonance (NMR) device, Waveguide Formμla, offering rapid, on-site screening and diagnostics. The Cambridge, Mass.-based startup is looking to advance the product for use in detecting infectious diseases and cancer.
Read More
2-21-MIX.png

Advanced med-tech companies MIXing it up with Canada’s first industry-led incubator

Feb. 25, 2020
By David Godkin
TORONTO – The head of a of Kitchener, Ontario-based surgical robotics firm has overseen the launch of Canada’s first industry-led hub dedicated to helping med-tech startups commercialize and scale up their technologies and businesses. Intellijoint Surgical Inc. CEO Armen Bakirtzian founded the Medical Innovation Xchange (MIX) for advanced startup companies that understand their markets and have completed initial steps for the design and manufacture of their technology.
Read More
Pill over molecule structures

Nicoya launches world’s first digital benchtop SPR system to accelerate drug discovery

Feb. 19, 2020
By David Godkin
TORONTO – Kitchener, Ontario-based Nicoya Life Sciences Inc. has followed up CA$10 million (US$7.6 million) in series A funding raised in January with its launch of “the world’s first digital benchtop surface plasmon resonance (SPR) system” to boost development of drug therapies.
Read More
Silhouette made of gears

Enclear scoops up $10M in series A funds for novel neurodegenerative disease treatment

Feb. 19, 2020
By Meg Bryant
Cambridge, Mass., startup Enclear Therapies Inc. has secured $10 million in series A financing led by 20/20 Healthcare Partners. The company is developing a device to aid in treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases by removing toxic proteins from cerebrospinal fluid (CSF).
Read More
Newco news

Reinvented Coimmune has a new IND and two clinical trials

Feb. 19, 2020
By Lee Landenberger
It’s been a rapid year of change for Coimmune Inc., which was incorporated only 12 months ago and now has FDA approval of an IND clearing the way for a phase IIb trial using CMN-001 to treat advanced metastatic renal cell carcinoma (mRCC).
Read More
Newco news

Medicinal cannabis company Zelira raises nearly AU$5 million as it gears up for commercialization

Feb. 18, 2020
By Tamra Sami
PERTH, Australia – With a capital raise of $AU4.58 million (US$3.07 million) under its belt, Zelira Therapeutics Ltd. will be better positioned to launch multiple medicinal cannabis products that are currently in late-stage clinical trials.
Read More
Kidney illustration

Serenno Medical introduces continuous automatic monitoring device for kidney function

Feb. 18, 2020
By David Ho
HONG KONG – Yokneam, Israel-based Serenno Medical Ltd. has unveiled a device for automatic monitoring and detection of kidney damage in patients. Known as Sentinel, the device is a continuous urine output (UO) monitor that measures urine flow rate and volume in real time.
Read More

Surgeons carry out first robotic supermicrosurgery

Feb. 14, 2020
By Nuala Moran
LONDON – Surgeons in the Netherlands have carried out what is claimed as the first human supermicrosurgery, connecting vessels of a diameter as low as 0.3 mm using a purpose-designed robotic system.
Read More
Previous 1 2 … 69 70 71 72 73 74 75 76 77 … 80 81 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Red dart and target against blue sky

    Unmasking the X: EPAC2 shifts the fragile X landscape

    BioWorld
    Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
  • Skin irritation on hands

    Recludix presents STAT1/3 inhibitors for dermatological diseases

    BioWorld Science
    Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing